Paid-members only Ticker Lane Featured $ATYR: The FDA Just Cleared aTyr's Second Shot. The Market Values the Company at Less Than Its Bank Account. aTyr Pharma got FDA alignment on a new Phase 3 for efzofitimod a year after an 83% one-day collapse. At $0.37, below net cash, the next sixty days decide the trade, not the science: a reverse-split vote and a Nasdaq deadline.
